Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prophylaxis of Chronic Graft-versus-host Disease (cGvHD) With or Without Anti-T-lymphocyte-globulin (ATG Fresenius) Prior Allogeneic Peripheral Stem Cell Transplantation From HLA-identical Siblings After Myeloablative Conditioning in Patients With Acute Leukemia: A Randomized Phase III-study
Brief Summary: This multicenter, prospective phase III-study is to compare the administration of ATG FRESENIUS to the NON-administration of ATG FRESENIUS in a myeloablative conditioning regimen followed by allogeneic hematopoeitic stem cell transplantation from an HLA-identical sibling in patients with acute Leukemia. This clinical trial is to show that the administration of ATG FRESENIUS reduces the risk of chronic Graft-versus-Host disease after allogeneic stem cell transplantation from HLA-identical siblings.


Options:
A: Arm Label: Ruxolitinib; Type: EXPERIMENTAL; Interventions: Drug: Ruxolitinib | Arm Label: Best Available Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Extracorporeal photopheresis (ECP), Drug: Low-dose methotrexate (MTX), Drug: Mycophenolate mofetil (MMF), Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus), Drug: Infliximab, Drug: Rituximab, Drug: Pentostatin, Drug: Imatinib, Drug: Ibrutinib | Intervention Type: DRUG; Name: Ruxolitinib; Assigned to Arm(s): Ruxolitinib | Intervention Type: DRUG; Name: Extracorporeal photopheresis (ECP); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Low-dose methotrexate (MTX); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Mycophenolate mofetil (MMF); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus); Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Imatinib; Assigned to Arm(s): Best Available Therapy | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Best Available Therapy
B: Arm Label: TBI + fludarabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conditioning regimen: TBI + Fludarabine | Arm Label: TLI + ATG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Conditioning regimen:TLI (8 Gy) + ATG | Intervention Type: DRUG; Name: Conditioning regimen: TBI + Fludarabine; Assigned to Arm(s): TBI + fludarabine | Intervention Type: DRUG; Name: Conditioning regimen:TLI (8 Gy) + ATG; Assigned to Arm(s): TLI + ATG
C: Arm Label: Thymoglobulin; Type: EXPERIMENTAL; Interventions: Biological: Anti-Thymocyte Globulin (Rabbit) | Arm Label: No Thymoglobulin; Type: OTHER; Interventions: Other: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin) | Intervention Type: BIOLOGICAL; Name: Anti-Thymocyte Globulin (Rabbit); Assigned to Arm(s): Thymoglobulin | Intervention Type: OTHER; Name: Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin); Assigned to Arm(s): No Thymoglobulin
D: Arm Label: A; Type: OTHER; Interventions: Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin) | Arm Label: B; Type: OTHER; Interventions: Drug: ATG FRESENIUS (Anti-Lymphocyte-Globulin) | Intervention Type: DRUG; Name: ATG FRESENIUS (Anti-Lymphocyte-Globulin); Assigned to Arm(s): A | Intervention Type: DRUG; Name: ATG FRESENIUS (Anti-Lymphocyte-Globulin); Assigned to Arm(s): B

Answer: D